Literature DB >> 28870117

Pseudotyped Lentiviral Vectors: One Vector, Many Guises.

Alok V Joglekar1, Salemiz Sandoval1.   

Abstract

Viruses have evolved specialized molecular mechanisms to transfer their genome efficiently into host cells. Viruses can be repurposed into viral vectors to achieve controlled gene transfer to desired cells. One of the most popular classes of vectors, lentiviral vectors (LVs), transduce mammalian cells efficiently. LVs are pseudotyped with various heterologous viral envelopes to alter their tropism. While the most common example is the envelope glycoprotein from vesicular stomatitis virus (VSVG), many other viral proteins have also been used. Pseudotyping LVs with a diverse set of naturally occurring or engineered viral envelopes has allowed targeted transduction of specific cell types. Many exciting studies are further uncovering new specificities and shortcomings of pseudotyped LVs. These studies will expand the toolbox to make LVs that cater to the specific requirements of transduction. This review provides a comprehensive overview of various viral envelope pseudotypes used with LVs, their specificities, advantages, and drawbacks.

Entities:  

Keywords:  lentiviral vector envelopes; pseudotyped lentiviral vect; pseudotypes

Mesh:

Substances:

Year:  2017        PMID: 28870117     DOI: 10.1089/hgtb.2017.084

Source DB:  PubMed          Journal:  Hum Gene Ther Methods        ISSN: 1946-6536            Impact factor:   2.396


  19 in total

1.  Assessment and streamlined preparation of low-cytotoxicity lentiviral vectors for mobilized human hematopoietic stem cell transduction.

Authors:  Paul T Toran; Martin Wohlfahrt; Julia Foye; Hans-Peter Kiem; Don M Wojchowski
Journal:  Exp Hematol       Date:  2020-05-27       Impact factor: 3.084

Review 2.  Therapeutic in vivo delivery of gene editing agents.

Authors:  Aditya Raguram; Samagya Banskota; David R Liu
Journal:  Cell       Date:  2022-07-06       Impact factor: 66.850

Review 3.  The delivery challenge: fulfilling the promise of therapeutic genome editing.

Authors:  Joost van Haasteren; Jie Li; Olivia J Scheideler; Niren Murthy; David V Schaffer
Journal:  Nat Biotechnol       Date:  2020-06-29       Impact factor: 54.908

Review 4.  Lessons learned from lung and liver in-vivo gene therapy: implications for the future.

Authors:  Joost van Haasteren; Stephen C Hyde; Deborah R Gill
Journal:  Expert Opin Biol Ther       Date:  2018-08-10       Impact factor: 4.388

Review 5.  Ebola Virus Entry: From Molecular Characterization to Drug Discovery.

Authors:  Cristiano Salata; Arianna Calistri; Gualtiero Alvisi; Michele Celestino; Cristina Parolin; Giorgio Palù
Journal:  Viruses       Date:  2019-03-19       Impact factor: 5.048

Review 6.  CRISPR/Cas9-mediated genome editing in nonhuman primates.

Authors:  Yu Kang; Chu Chu; Fang Wang; Yuyu Niu
Journal:  Dis Model Mech       Date:  2019-10-16       Impact factor: 5.758

Review 7.  Vectored Immunotherapeutics for Infectious Diseases: Can rAAVs Be The Game Changers for Fighting Transmissible Pathogens?

Authors:  Wei Zhan; Manish Muhuri; Phillip W L Tai; Guangping Gao
Journal:  Front Immunol       Date:  2021-05-11       Impact factor: 7.561

8.  Non-genotoxic conditioning facilitates hematopoietic stem cell gene therapy for hemophilia A using bioengineered factor VIII.

Authors:  Athena L Russell; Chengyu Prince; Taran S Lundgren; Kristopher A Knight; Gabriela Denning; Jordan S Alexander; Jaquelyn T Zoine; H Trent Spencer; Shanmuganathan Chandrakasan; Christopher B Doering
Journal:  Mol Ther Methods Clin Dev       Date:  2021-05-05       Impact factor: 6.698

9.  Efficient Nonviral Stable Transgenesis Mediated by Retroviral Integrase.

Authors:  Chang-Ying Chiang; Gloria Denise Ligunas; Wei-Chun Chin; Chih-Wen Ni
Journal:  Mol Ther Methods Clin Dev       Date:  2020-05-03       Impact factor: 6.698

10.  Intramuscular Delivery of Gene Therapy for Targeting the Nervous System.

Authors:  Andrew P Tosolini; James N Sleigh
Journal:  Front Mol Neurosci       Date:  2020-07-17       Impact factor: 5.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.